NYEE HomeThe New York Eye and Ear Infirmary
Patient InfoHealthcare ProfessionalsSpecialties & ServicesSupport NYEEAbout Us
  Current Research
Clinical Trials in Ophthalmology
Ophthalmology
Research

Otolaryngology
Research

Pathology
& Laboratory Medicine
Research

Plastic &
Reconstructive
Surgery
Research

Institutional
Review Board
(IRB)

 
printer-friendly version of this pagePrinter-Friendly Page large print version of this pageLarge Print Version 

A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients

Principal Investigator: Alessandra Bertolucci, MD

Enrollment Status: Open

Objective:  Synthetic dopamine agonists including study drugs have shown benefit in Parkinson's Disease (PD) as an adjuvant therapy. Drugs affect neurotransmitters in the retina where dopamine has been shown to be reduced and dependant neurons appear swollen and distorted. This study is designed as a longitudinal study to rule out effects on the retina.

Eligibility:  Contact Principal Investigator/Coordinator

Contact Information:  

  • Principal Investigator: Alessandra Bertolucci, MD at (212) 614-8302
  • Katy Tai, CR Manager (212) 979-4251
Home > Current Research > Clinical Trials in Ophthalmology > A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of pramipexole IR versus ropinirole in early Parkinson's Disease patients